Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Prolonged aPTT in Patients with Covid-19 In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus anticoagulant...

[1]  Toshiaki Iba,et al.  The unique characteristics of COVID-19 coagulopathy , 2020, Critical Care.

[2]  D. Roccatello,et al.  Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients , 2020, Internal and Emergency Medicine.

[3]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[4]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[5]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[6]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[7]  B. Cantinieaux,et al.  Applying a direct aPTT ratio (PlatelinLS/ActinFS) permits to identify rapidly and reliably a bleeding‐related factor deficiency or a lupus anticoagulant sequential to an isolated prolongation of aPTT in paediatric pre‐operative screening , 2016, European journal of haematology.

[8]  M. Laffan,et al.  Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis , 2013, International journal of laboratory hematology.

[9]  M. Makris,et al.  The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal , 2011, International journal of laboratory hematology.

[10]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[11]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[12]  D. W. Jones,et al.  Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII , 2000, British journal of haematology.

[13]  S. Kitchen,et al.  Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies. , 1998, Clinical and laboratory haematology.